Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Belatacept/mycophenolate-mofetil/sirolimus

Off-label use and various toxicities: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wright M, et al. Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatric Transplantation 25: 1-5, No. 6, Sep 2021. Available from: URL: http://doi.org/10.1111/petr.14041 Wright M, et al. Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatric Transplantation 25: 1-5, No. 6, Sep 2021. Available from: URL: http://​doi.​org/​10.​1111/​petr.​14041
Metadaten
Titel
Belatacept/mycophenolate-mofetil/sirolimus
Off-label use and various toxicities: 2 case reports
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15000-y

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Tozinameran

Case report

Fluorouracil